PharmTech Europe News

This approval makes the drug the first and only targeted medicine indicated to treat this population of children in Europe and the United States.

Stevanato Group will support development and production of pre-fillable syringes for use in Recipharm’s soft mist inhalers.

Sandoz, a Novartis division, is expected to invest at least $400 million to build a new biologics manufacturing facility in Lendava, Slovenia, to support growing demand for biosimilars.

Sumitovant Bipharma has completed its acquisition of Myovant Sciences for approximately $1.7 billion.

Janssen has received a positive opinion from EMA for AKEEGA plus prednisone or prednisolone for the treatment of BRCA1/2 gene-mutated metastatic castration resistant prostate cancer.

EnteroBiotix is harnessing the power of the microbiome to target an array of diseases.

Technological advances will help ease pressure on pharma supply chains, allowing for greater visibility and less uncertainty.

Soaring energy costs are compounding the challenges currently being faced by the European bio/pharma industry.

CHMP recommended the approval of AbbVie’s RINVOQ (upadacitinib) as a treatment for adults with moderate-to-severe Crohn’s disease.

Orchard Therapeutics has announced an agreement which will enable reimbursed access to Libmeldy for all eligible MLD patients in Sweden.

Roche’s Phase III global program, centered around the biologic crovalimab as a treatment for paroxysmal nocturnal haemoglobinuria, showed the drug was non-inferior to current standards of care.

iotaSciences isoPick is designed to expand handling solutions for cell biology and gene therapy applications.

The European bio/pharma industry’s high regulatory standards and GMP requirements are set to position the region as a frontrunner for pharmaceutical‑grade manufacturing of cannabis-based medicines.

Although some headway is being made into more gender-diverse executive levels in pharma, much more work is still needed.

CRB’s latest industry report includes an expanded audience to include many European countries, which has provided some interesting insights.

Chiesi will acquire Amryt Pharma, a commercial-stage biopharmaceutical company, in a deal worth up to $1.47 billion.

The company was awarded the Terra Carta Seal in recognition of its commitment to creating a sustainable future.

Ipsen’s $952 million acquisition of Albireo is designed to bolster the company's rare disease portfolio.

Sartorius and RoosterBio will work together to address purification challenges and establish scalable downstream manufacturing processes for exosome-based therapies.

Bio/pharma has evolved and adapted to a variety of challenges in 2022, but what might be on the cards for the industry in 2023?

In light of increasingly stringent sustainability requirements, bio/pharma companies need to make sure they formulate effective ESG strategies.

TreeFrog Therapeutics is leaping ahead in cell therapies through resources such as new technologies and investor partnerships.

The latest report from Clarivate has been published, highlighting 15 potential blockbusters to watch out for in 2023, the majority of which are personalized medicines.

Does the new regulatory framework have the potential to incentivise R&D investment in rare diseases?

Pharmaceutical Technology Europe got the scoop on Agilent's new Dissolution Testing Centre of Excellence in Craven Arms, UK.

The European Human Medicines Directive and Regulation is due to be updated by the end of 2022, but what changes are on the cards?

Anti-obesity drugs have the potential to be the next blockbusters, according to market analysis.

Aptamer’s new 18,000 ft² facility will expand the company's capacity to deliver novel binders for bioprocessing, diagnostic, and drug development.

The agreement aims to develop integrated technology for large-scale exosome production.

NMPA has approved Ferinject in China for the treatment of iron deficiency or iron deficiency anemia.